Valoid Tablets

  • Name:

    Valoid Tablets

  • Company:
    info
  • Active Ingredients:

    Cyclizine Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 07/08/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 4/5/2015
print

Print ViewKeyword Search SmPC

ADVANZ Pharma

advanz-full-rgb_1543842253

Company Products

Medicine NameActive Ingredients
Medicine Name Celevac 500 mg tablets Active Ingredients Methylcellulose
Medicine Name Chloromycetin 0.5% w/v Redidrops Eye Drops, Solution. Active Ingredients Chloramphenicol
Medicine Name Clarithromycin 500 mg, Powder for Concentrate for Solution for Infusion Active Ingredients Clarithromycin lactobionate
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate, Paracetamol
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Codipar 15mg/500mg Effervescent Tablets Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Cyclimorph 10 Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Cyclimorph 15 Solution for Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Detrunorm XL 30 mg modified-release capsules Active Ingredients Propiverine hydrochloride
Medicine Name Eltroxin 100 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Eltroxin 50 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Erythrocin 250mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin 500mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin IV Lactobionate 1.0g Powder for Solution for Infusion Active Ingredients Erythromycin Lactobionate
Medicine Name Erythromycin Tablets BP 250mg. Active Ingredients Erythromycin
Medicine Name Erythroped Adult Tablets Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped Forte SF 500mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped PI SF 125mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped SF 250mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Fucithalmic 10 mg/g Viscous eye drops, suspension Active Ingredients Fusidic Acid Hemihydrate
Medicine Name Genticin 80 mg/2 ml Solution for Injection Active Ingredients Gentamicin sulfate
Medicine Name Genticin Eye/Ear Drops Solution Active Ingredients Gentamicin sulfate
Medicine Name Gentisone HC 0.3% w/v & 1.0% w/v Ear Drops, Suspension Active Ingredients Gentamicin sulfate, Hydrocortisone Acetate
Medicine Name HYTRIN Tablets 10mg Active Ingredients Terazosin monohydrochloride dihydrate
Medicine Name HYTRIN Tablets 2mg Active Ingredients Terazosin monohydrochloride dihydrate
1 - 0 of 44 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 7 August 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 4 May 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 May 2015 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4 - Clinical particulars
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5 - Pharmacological properties
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6 - Pharmaceutical particulars
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Update sections 1-4, 4.1- 4.9, 5-5.3, 6-6.6, 7, 8, , 9 & 10 of the SmPC and relevant sections of the PIL

Updated on 4 May 2015 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4 - Clinical particulars
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5 - Pharmacological properties
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6 - Pharmaceutical particulars
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation

Free text change information supplied by the pharmaceutical company

 Update sections 1-4, 4.1- 4.9, 5-5.3, 6-6.6, 7, 8, , 9 & 10 of the SmPC and relevant sections of the PIL

Updated on 15 June 2012 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

 

In section 1 the trade name ‘Valoid Tablets 50mg’ has been added.

 

In section 2 the quantity of the excipient lactose has been added.

 

In section 3 the description of the tablet has been updated. The statement ‘The tablet can be divided into two equal halves’.

 

In section 4.1 the indications have been updated to read:

Valoid is indicated for the prevention and treatment of nausea and vomiting including

•           Motion sickness.

•           Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period.

•           Vomiting associated with radiotherapy especially for breast cancer since Cyclizine does not elevate prolactin levels.

 

In section 4.2 the statement ‘Route of administration – Oral’ has been added.

 

In section 4.4 (special warnings) a caution regarding patients with epilepsy and hepatic disease, severe heart failure, porphyria and neuromuscular disease has been added.  Reports of euphoric/hallucinatory effects and transient paralysis have been added as further cautions.

 

In section 4.6 the details of fertility studies have been removed.

 

In section 4.7 the paragraph has been reworded.

 

In section 4.8 the side effects have been reorganised into system order class. A further warning regarding IV use is mentioned.

 

In section 5.1 the ATCcode and pharmacotherapeutic group has been added.

 

In section 5.2 the pharmacokinetic properties have been updated to reflect the oral formulation.

 

In section 5.3 two sections entitled teratogenicity and fertility have been added with information in each section.

 

In section 6.5 the nature of the container has been updated.

 

In section 6.6 the title of the sub section has been updated to read: ‘Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product’

 

In section 10 the date has been updated to April 2009.

Updated on 15 June 2012 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

In section 1 the trade name ‘Valoid Tablets 50mg’ has been added.

 

In section 2 the quantity of the excipient lactose has been added.

 

In section 3 the description of the tablet has been updated. The statement ‘The tablet can be divided into two equal halves’.

 

In section 4.1 the indications have been updated to read:

Valoid is indicated for the prevention and treatment of nausea and vomiting including

•           Motion sickness.

•           Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period.

•           Vomiting associated with radiotherapy especially for breast cancer since Cyclizine does not elevate prolactin levels.

 

In section 4.2 the statement ‘Route of administration – Oral’ has been added.

 

In section 4.4 (special warnings) a caution regarding patients with epilepsy and hepatic disease, severe heart failure, porphyria and neuromuscular disease has been added.  Reports of euphoric/hallucinatory effects and transient paralysis have been added as further cautions.

 

In section 4.6 the details of fertility studies have been removed.

 

In section 4.7 the paragraph has been reworded.

 

In section 4.8 the side effects have been reorganised into system order class. A further warning regarding IV use is mentioned.

 

In section 5.1 the ATCcode and pharmacotherapeutic group has been added.

 

In section 5.2 the pharmacokinetic properties have been updated to reflect the oral formulation.

 

In section 5.3 two sections entitled teratogenicity and fertility have been added with information in each section.

 

In section 6.5 the nature of the container has been updated.

 

In section 6.6 the title of the sub section has been updated to read: ‘Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product’

 

In section 10 the date has been updated to April 2009.

Updated on 14 August 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 August 2008 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 29 August 2007 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 29 August 2007 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 August 2006 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

 

Note: Additional text is shown in red, removed text is shown with strikethrough.

 

 

2.            QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Tablets containing 50 mg cyclizine hydrochloride.

 

For excipients, see 6.1

 

 

4.8            Undesirable effects

 

Urticaria, drug rash, drowsiness, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded.  Cholestatic jaundice has occurred in association with cyclizine.

 

Single case reports have been documented of fixed drug eruption, generalized chorea, hypersensitivity hepatitis and agranulocytosis.

 

Other Central Nervous effects which have been reported rarely include dystonia, dyskinesia, extrapyrimidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness, paraesthesia and transient speech disorders.

 

Rare reports of cholestatic hepatitis and hypersensitivity reactions, including anaphylaxis, angiodema, allergic skin reactions and bronchospasm, have been reported in association with cyclizine.  There have also been a few reports of fixed drug eruption, apnoea, generalized chorea, hypersensitivity hepatitis, hepatic dysfunction and agranulocytosis.

 

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

 

1st April 1979/ 1st April 1999 2004

 

10.       DATE OF REVISION OF THE TEXT

 

November 2005

 

Updated on 4 August 2006 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

Note: Additional text is shown in red, removed text is shown with strikethrough.

 

 

2.            QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Tablets containing 50 mg cyclizine hydrochloride.

 

For excipients, see 6.1

 

 

4.8            Undesirable effects

 

Urticaria, drug rash, drowsiness, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded.  Cholestatic jaundice has occurred in association with cyclizine.

 

Single case reports have been documented of fixed drug eruption, generalized chorea, hypersensitivity hepatitis and agranulocytosis.

 

Other Central Nervous effects which have been reported rarely include dystonia, dyskinesia, extrapyrimidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness, paraesthesia and transient speech disorders.

 

Rare reports of cholestatic hepatitis and hypersensitivity reactions, including anaphylaxis, angiodema, allergic skin reactions and bronchospasm, have been reported in association with cyclizine.  There have also been a few reports of fixed drug eruption, apnoea, generalized chorea, hypersensitivity hepatitis, hepatic dysfunction and agranulocytosis.

 

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

 

1st April 1979/ 1st April 1999 2004

 

10.       DATE OF REVISION OF THE TEXT

 

November 2005

 

Updated on 10 June 2005 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 10 June 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)